Dr. R. Rox Anderson Joins BioChemics Scientific Advisory Board to Advise on Development of Dermatological Products

Business Wire, June 3, 2008

DANVERS, Mass. -- BioChemics, Inc., a company "pioneering transdermal drug delivery," is pleased to announce that Dr. R. Rox Anderson, Professor at Harvard Medical School, adjunct professor at MIT, and Director of the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) in Boston has elected to serve as a member of the Company's Scientific Advisory Board (SAB). Dr. Anderson will be providing strategic input into the development of the company's targeted, topical products to treat a variety of dermatological disorders.

"To add to our SAB an internationally recognized pioneer in the field of Photomedicine such as Dr. Anderson, with his longstanding success in treating patients with photo/laser therapy is a significant addition to our SAB," said John J. Masiz., President and CEO, BioChemics, Inc. "We believe there is a significant market opportunity for developing topical based products that enhance the utility and effectiveness of Phototherapy to treat a variety of dermatological disorders."

An estimated 53 million laser operations are performed annually in the US. These procedures are used to help treat birthmarks, pigmented lesions, rosacea, tattoos, hypertrichosis and other conditions. Lasers have revolutionized the practice of cosmetic surgery and related services. For example, in hair removal alone, where laser therapy has just made an initial entry, the U.S. market is estimated to bet $1 billion.

"I am extremely excited to be asked to contribute my knowledge and expertise toward the success of a company such as BioChemics," said Dr. R. Rox Anderson, Professor at Harvard Medical School, adjunct professor at MIT, and Director of the Wellman Center for Photomedicine at MGH in Boston. Dr. Anderson adds, "Topical products that can be used to enhance the outcomes of other treatments are a welcome addition, not only to patients, but also to physicians."

About Photomedicine

Photomedicine is an interdisciplinary branch of medicine that involves the study and application of light with respect to health and disease. Light based therapeutic and diagnostic interventions can often be designed to be minimally invasive and selectively targeted. Photomedicine may be related to the practice of various fields of medicine including dermatology, surgery, dentistry, optical diagnostics, cardiology, and oncology. Photomedicine is currently in a renaissance of rapid technological and clinical progress.

About Dr. R. Rox Anderson

Dr. R. Rox Anderson is a professor at Harvard Medical School, an adjunct professor at MIT, and director of the Wellman Center for Photomedicine at Massachusetts General Hospital in Boston. Wellman is the world's largest academic facility dedicated to photomedicine. After graduating from MIT, Dr. Anderson received his M.D. degree from Harvard. He conceived and developed dermatologic surgery using selectively-absorbed laser pulses, which is now the preferred basis for treatment of birthmarks, pigmented lesions, tattoos, hypertrichosis and other conditions. He has made many contributions to the understanding and development of laser-tissue interactions, tissue optics, photodynamic therapy, and optical diagnostics. Dr. Anderson also practices dermatology, teaches at Harvard and MIT, and conducts research at the Wellman Center for Photomedicine. Active research includes diagnostic tissue imaging and spectroscopy, photodynamic therapy, mechanisms of laser-tissue interactions, low-level light effects and novel therapies. Dr. Anderson received the Ellet H. Drake and William Mark awards from this Society, and serves on the editorial board of its journal.

About BioChemics, Inc.

BioChemics is a pharmaceutical company that has developed a novel, transdermal drug delivery system that for the first time may allow almost any drug to be efficiently delivered through the skin. The transdermal technology, called VALE[R] (Vaso-active Lipid Encapsulated), may allow a substantial portion of the pharmacopeia to be re-engineered, turning oral drugs into transdermals that are safer (no gastro-intestinal problems), cheaper and potentially faster acting (applied directly to the treated area) than oral equivalents. The company's focus is on multi-billion dollar market opportunities currently underserved by existing therapies. The company's two lead clinical products focus on treating diabetic neuropathy and osteoarthritis. Founded in 1989, the Company is headquartered in Danvers, Mass. Additional information is available at www.biochemics.com.

VALE[R] is a registered trademark of BioChemics, Inc.